StockData
Insight Molecular Diagnostics Inc. logo

Insight Molecular Diagnostics Inc. (IMDX) stock

IMDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$1.78−0.08 (-4.30%)

Close on Nov 17, 2026Market cap $58.25MP/E –Yield –

Insight Molecular Diagnostics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Insight Molecular Diagnostics's operating cash flow for the twelve months ending Jun 30, 2026 was -$27.08M. For fiscal 2025 it was -$22.18M. The highest annual figure on record is -$1.16M in fiscal 2014.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$22.18M–
FY2024Dec 31, 2024-$20.69M–
FY2023Dec 31, 2023-$23.33M–
FY2022Dec 31, 2022-$45.57M–
FY2021Dec 31, 2021-$35.94M–
FY2020Dec 31, 2020-$25.98M–
FY2019Dec 31, 2019-$19.72M–
FY2018Dec 31, 2018-$11.65M–
FY2017Dec 31, 2017-$13.39M–
FY2016Dec 31, 2016-$7.52M–
FY2015Dec 31, 2015-$4.23M–
FY2014Dec 31, 2014-$1.16M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$9.27M–
Q1 FY2026Mar 31, 2026-$7.64M–
Q4 FY2025Dec 31, 2025-$5.55M–
Q3 FY2025Sep 30, 2025-$4.63M–
Q2 FY2025Jun 30, 2025-$6.17M–
Q1 FY2025Mar 31, 2025-$5.84M–
Q4 FY2024Dec 31, 2024-$5.35M–
Q3 FY2024Sep 30, 2024-$5.53M–
Q2 FY2024Jun 30, 2024-$5.98M–
Q1 FY2024Mar 31, 2024-$3.83M–
Q4 FY2023Dec 31, 2023-$4.42M–
Q3 FY2023Sep 30, 2023-$3.77M–
Q2 FY2023Jun 30, 2023-$6.83M–
Q1 FY2023Mar 31, 2023-$8.30M–
Q4 FY2022Dec 31, 2022-$9.65M–
Q3 FY2022Sep 30, 2022-$11.40M–
Q2 FY2022Jun 30, 2022-$11.25M–
Q1 FY2022Mar 31, 2022-$13.28M–
Q4 FY2021Dec 31, 2021-$7.07M–
Q3 FY2021Sep 30, 2021-$10.98M–
Q2 FY2021Jun 30, 2021-$8.06M–
Q1 FY2021Mar 31, 2021-$9.84M–
Q4 FY2020Dec 31, 2020-$6.14M–
Q3 FY2020Sep 30, 2020-$6.01M–
Q2 FY2020Jun 30, 2020-$6.96M–
Q1 FY2020Mar 31, 2020-$6.87M–
Q4 FY2019Dec 31, 2019-$5.31M–
Q3 FY2019Sep 30, 2019-$4.85M–
Q2 FY2019Jun 30, 2019-$2.84M–
Q1 FY2019Mar 31, 2019-$6.72M–
Q4 FY2018Dec 31, 2018-$2.46M–
Q3 FY2018Sep 30, 2018-$2.48M–
Q2 FY2018Jun 30, 2018-$3.96M–
Q1 FY2018Mar 31, 2018-$2.75M–
Q4 FY2017Dec 31, 2017-$3.34M–
Q3 FY2017Sep 30, 2017-$3.47M–
Q2 FY2017Jun 30, 2017-$3.28M–
Q1 FY2017Mar 31, 2017-$3.29M–
Q4 FY2016Dec 31, 2016-$2.51M–
Q3 FY2016Sep 30, 2016-$1.03M–

More Insight Molecular Diagnostics figures

See a number that looks wrong?